基于树突状细胞的免疫治疗用于已切除胰腺癌患者
这项单中心、开放标签、单臂I/II期试验纳入38例胰腺癌切除并完成标准治疗无复发患者,给予负载同种异体间皮瘤肿瘤细胞裂解物的自体树突状细胞疫苗。中位随访25.5个月,26例(68%)未复发,估计2年无复发生存率为64%,达到≥60%的主要终点。
要点
- 38例可评估患者中26例(68%)在中位随访25.5个月时未出现疾病复发。
- 估计2年无复发生存率为64%,达到预设的≥60%临床有意义改善阈值。
- 疫苗接种后外周活化CD4+ T细胞富集,体外可检测到治疗诱导的免疫反应。
核心结论
- 胰腺癌切除术后完成标准治疗并接受辅助树突状细胞免疫治疗,2年无复发生存率达到≥60%的主要终点。
- 这些结果值得未来开展随机试验。
研究设计与样本
- 单中心、开放标签、单臂、I/II期联合试验。
- 主要终点为2年无复发生存率,≥60%定义为临床有意义改善。
- 纳入胰腺癌切除术后完成标准治疗且横断面影像无复发患者。
- 给予负载同种异体间皮瘤肿瘤细胞裂解物(含胰腺导管腺癌也表达的抗原)的自体树突状细胞。
- 38例患者纳入主要终点分析,男性47%、女性53%,中位年龄62岁(IQR 55-68)。
主要发现
- 28例(74%)接受五次树突状细胞疫苗接种并完成研究方案,3例(8%)接受四次,7例(16%)接受三次。
- 中位随访25.5个月后,26例(68%)未出现疾病复发。
- 估计2年无复发生存率为64%。
- 疫苗接种导致循环活化CD4+ T细胞富集,并在体外检测到治疗诱导的免疫反应。
- 对切除的孤立肺转移灶行T细胞受体测序分析显示疫苗特异性T细胞浸润。
关键数值与推荐
- 主要终点2年无复发生存率≥60%定义为临床有意义改善,本研究估计值为64%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Immunotherapies have shown limited responses in patients with advanced pancreatic cancer. Recently, we reported that dendritic cell (DC)-based immunotherapy induced T-cell responses against pancreatic cancer antigens. The primary objective of this study was to determine the efficacy of DC-based immunotherapy to prevent recurrence of disease. METHODS: This was a single-center, open-label, single-arm, combined phase I/II trial. The primary end point was the 2-year recurrence-free survival (RFS) rate. A 2-year RFS rate of ≥60% was defined as a clinically meaningful improvement. We included patients with pancreatic cancer after resection and completion of standard-of-care (SOC) treatment without recurrent disease on cross-sectional imaging. Patients were treated with autologous DCs pulsed with an allogeneic mesothelioma tumor cell lysate, comprising antigens also expressed in pancreatic ductal adenocarcinoma. RESULTS: Thirty-eight patients were included in the analysis of the primary end point (47% male, 53% female). The median age was 62 years (IQR, 55-68). Twenty-eight patients (74%) received five DC vaccinations and completed the study protocol. Three patients (8%) received four vaccinations, and seven patients (16%) received three vaccinations. After a median follow-up of 25.5 months, 26 patients (68%) had not developed recurrence of disease. The estimated 2-year RFS was 64%. Vaccination led to the enrichment of circulating activated CD4+ T cells and the detection of treatment-induced immune responses in vitro. T-cell receptor-sequencing analyses of a resected solitary lung metastasis showed influx of vaccine-specific T cells. CONCLUSION: This study reached its primary end point of a 2-year RFS rate of ≥60% following pancreatectomy after SOC treatment and adjuvant DC-based immunotherapy in patients with pancreatic cancer. These results warrant a future randomized trial.
引用
- van 't Land FR, Willemsen M, Bezemer K, et al. Dendritic Cell-Based Immunotherapy in Patients With Resected Pancreatic Cancer. J Clin Oncol. 2024. PMID: 38950309. doi:10.1200/JCO.23.02585
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。